James I. Geller, MD

My Biography & Research My Locations My Education My Publications

Director - Liver, Kidney and Retinoblastoma Programs, Cancer and Blood Diseases Institute

Director, Advanced Cancer Therapy Network, Cancer and Blood Disease Institute

Director, Pilot Translational Core Grant Program, Center for Clinical and Translational Science and Training

Professor, UC Department of Pediatrics

james.geller@cchmc.org

513-636-6332

513-636-3549

Board Certified

My Biography & Research

Biography

James I. Geller, MD, started in the Division of Oncology at Cincinnati Children's Hospital Medical Center as an assistant professor within the UC Department of Pediatrics in 2004. Currently, he is the medical director of Liver and Renal Tumor Programs and co-director of the Retinoblastoma Program.

His primary academic interest is the development of novel therapy options for infants, children, adolescents and young adults with solid tumors. At the institutional level, he achieves this through direct patient care and by leading our teams in clinical and research efforts in my specialty areas at Cincinnati Children’s Hospital Medical Center. At the national level, he participates as a member of the Children’s Oncology Group (COG) Renal Tumor (RTC), Liver Tumor, Retinoblastoma and Central Nervous System Committees; He functions as vice chair for the RTC and liaison to the COG Developmental Therapeutics Committee (DVL) and Pediatric Preclinical Testing Program as well as chair both the RTC Developmental Therapeutics Working Group and the COG High Risk Renal Tumors Protocols including AREN1721 (focused on immunotherapy and anti-angiogenic therapy for TFE Renal Cell Carcinoma), AREN1921 (focused on relapsed and anaplastic Wilms tumor), and has drafted the next concept for study of epigenetic therapy plus chemotherapy for treatment of rhabdoid tumor. He also serves as co-chair of the COG liver tumor protocol, the Pediatric Hepatic International Tumor Trial (PHITT); AHEP1531.

It is his goal to help facilitate the development of novel therapy for young patients affected with solid tumors. Current areas of expansion include the establishment of the Translational RCC Research Initiatives including a registry for TFE RCC, and development of data harmonization and treatment optimization for relapsed pediatric liver cancers. Integration of cellular and immunotherapy, as well as novel interventional therapeutics, remains a priority.

Clinical Interests

Pediatric oncology; solid tumors; liver tumors; kidney tumors; retinoblastoma; rare tumors; intraarterial chemotherapy and intraarterial radiotherapy for treatment of select cancers

Research Interests

Liver tumors; kidney tumors; retinoblastoma; new drug development; novel interventional therapeutics: intra-arterial chemotherapy, intra-arterial radiotherapy, high intensity focused ultrasound (HIFU)

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Cancer Blood Disease Institute, Kidney Tumor Clinic, Liver Tumor Program, Retinoblastoma, Oncology, Cancer and Blood Diseases Institute, Pancreas Care Center

My Locations

Burnet Campus

Burnet Campus

3333 Burnet Ave.

Cincinnati, Ohio 45229-3039

513-636-4200

Directions From
Liberty Campus

Liberty Campus

7777 Yankee Road

Liberty Township, Ohio 45044

1-513-803-9600

Directions From

My Education

BA: Chemistry, Dartmouth College, Hanover, NH.

MD: Sackler School of Medicine, Tel Aviv University, 1997.

Residency: Pediatrics, New York Medical College, 2000.

Fellowship: Pediatric Hematology/Oncology, St Jude Children's Research Hospital, 2004.

Certification: Pediatrics, 2000, 2007; Pediatric Hematology/Oncology, 2005.

My Publications

Geller JI, Fox E, Turpin BK, Goldstein SL, Liu X, Minard CG, Kudgus RA, Reid JM, Berg SL, Weigel BJ. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group Phase 1 and Pilot Consortium Trial (ADVL1315). Cancer. 2018 Nov 5.

D'Souza AM, Shah R, Gupta A, Towbin AJ, Alonso M, Nathan JD, Bondoc A, Tiao G, Geller JI. Surgical management of children and adolescents with upfront completely resected hepatocellular carcinoma. Pediatr Blood Cancer. 2018 Nov;65(11):e27293.

Geller JI. Current standards of care and future directions for “high-risk” pediatric renal tumors: Anaplastic Wilms tumor and rhabdoid tumor. Urol Oncol. 2016 Jan;34(1):50-56.

Michaels ST, Abruzzo TA, Augsburger JJ, Corrêa ZM, Lane A, Geller JI. Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience. J Ped Hem Oncol. 2016 Jan;38(1):65-69.

Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ, Naranjo A, Dome JS, Perlman EJ. Characterization of Adolescent and Pediatric Renal Cell Carcinoma, a Report from the Children’s Oncology Group Study AREN03B2. Cancer. 2015 Jul 15;121(14):2457-64.

Dix DB, Seibel NL, Chi YY, Khanna G, Gratias E, Anderson JR, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Wagner E, Grundy PE, Fernandez CV, Dome JS. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol. 2018 Jun 1;36(16):1564-1570.

Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, Anderson JR, Grundy PE, Dome JS. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol. 2018 Jan 20;36(3):254-261.

Geller JI, Perentesis JP, Ahern CH, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ197, IND#112603) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study. Pediatr Blood Cancer. 2017 Nov;64(11).

Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins M. Translocation Renal Cell Carcinoma: Lack of Negative Impact due to Lymph Node Spread. Cancer. 2008 Apr 1;112(7):1607-16.